Cullinan Total Current Liabilities from 2010 to 2025
| CGEM Stock | USD 7.89 0.28 3.68% |
Total Current Liabilities | First Reported 2012-03-31 | Previous Quarter 24.2 M | Current Value 30.6 M | Quarterly Volatility 13.3 M |
Check Cullinan Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cullinan Oncology's main balance sheet or income statement drivers, such as Interest Expense of 679 M, Selling General Administrative of 56.7 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 28.86, Ptb Ratio of 0.88 or Days Sales Outstanding of 0.0. Cullinan financial statements analysis is a perfect complement when working with Cullinan Oncology Valuation or Volatility modules.
Cullinan | Total Current Liabilities | Build AI portfolio with Cullinan Stock |
Latest Cullinan Oncology's Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Cullinan Oncology LLC over the last few years. Total Current Liabilities is an item on Cullinan Oncology balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Cullinan Oncology LLC are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Cullinan Oncology's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cullinan Oncology's overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Cullinan Total Current Liabilities Regression Statistics
| Arithmetic Mean | 9,089,879 | |
| Geometric Mean | 1,216,947 | |
| Coefficient Of Variation | 136.33 | |
| Mean Deviation | 10,623,510 | |
| Median | 1,324,000 | |
| Standard Deviation | 12,392,463 | |
| Sample Variance | 153.6T | |
| Range | 32.1M | |
| R-Value | 0.88 | |
| Mean Square Error | 38.5T | |
| R-Squared | 0.77 | |
| Slope | 2,278,425 | |
| Total Sum of Squares | 2303.6T |
Cullinan Total Current Liabilities History
About Cullinan Oncology Financial Statements
Cullinan Oncology investors utilize fundamental indicators, such as Total Current Liabilities, to predict how Cullinan Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 30.6 M | 32.2 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Cullinan Oncology Correlation against competitors. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.